Trial Profile
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms HOPE; HOPE-KIDS 1
- Sponsors Global Blood Therapeutics
- 26 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Sep 2023 Planned number of patients changed from 155 to 148.
- 11 Sep 2023 Planned End Date changed from 1 Dec 2023 to 4 Jan 2025.